Skip to main content
SpringerLink
Log in

Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Accession codes

Accessions

Gene Expression Omnibus

References

  1. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371: 221–226.

    Article  CAS  PubMed  Google Scholar 

  2. Huang Z, Dore LC, Li Z, Orkin SH, Feng G, Lin S et al. GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol 2009; 29: 5168–5180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fadilah SA, Cheong SK, Roslan H, Rozie-Hanisa M, Yen GK . GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome. Leukemia 2002; 16: 1563–1565.

    Article  CAS  PubMed  Google Scholar 

  4. Shimamoto T, Ohyashiki K, Ohyashiki JH, Kawakubo K, Fujimura T, Iwama H et al. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 1995; 86: 3173–3180.

    CAS  PubMed  Google Scholar 

  5. Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F . Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol 2009; 84: 79–86.

    Article  CAS  PubMed  Google Scholar 

  6. Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S et al. GATA-1 and GATA-2 binding to 3′ enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia 2009; 23: 1270–1277.

    Article  CAS  PubMed  Google Scholar 

  7. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005; 24: 1976–1987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lahortiga I, Vazquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Gozzetti A et al. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer 2004; 40: 179–189.

    Article  CAS  PubMed  Google Scholar 

  9. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE . Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28: 2739–2747.

    Article  CAS  PubMed  Google Scholar 

  10. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195–5201.

    Article  CAS  PubMed  Google Scholar 

  11. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605–1616.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Fondo de Investigación Sanitaria (FIS) del Instituto Carlos III (FI05/00497), Ministerio Educación y Ciencia (SAF2005/06425), Ministerio Ciencia e Innovación (PI081687), Departamento Salud del Gobierno de Navarra (14/2008), ISCIII-RTICC (RD06/0020/0078) and Fundación para la Investigación Médica Aplicada y UTE (Spain). We thank María J Larráyoz for technical assistance.

Author information

Authors and Affiliations

  1. Division of Oncology, Laboratory of Genetics, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain

    C Vicente, I Vazquez, A Conchillo, M A García-Sánchez, N Marcotegui & M D Odero

  2. Department of Genetics, University of Navarra, Pamplona, Spain

    C Vicente, M J Calasanz & M D Odero

  3. Department of Medical Pathology, Hospital Universitario La Fe, Valencia, Spain

    O Fuster

  4. Department of Hematology, Hospital Universitario, Salamanca, Spain

    M González

  5. Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium,

    I Lahortiga

Authors
  1. C Vicente
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Conchillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M A García-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Marcotegui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Fuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M González
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M J Calasanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I Lahortiga
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M D Odero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M D Odero.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vicente, C., Vazquez, I., Conchillo, A. et al. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia 26, 550–554 (2012). https://doi.org/10.1038/leu.2011.235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.235

  • Springer Nature Limited

This article is cited by

Search

Navigation